Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb;42(2):193-5.
doi: 10.3899/jrheum.141042. Epub 2014 Dec 15.

Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety

Rossella Reggia  1 , Franco Franceschini  2 , Angela Tincani  2 , Ilaria Cavazzana  2
Affiliations

Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety

Rossella Reggia et al. J Rheumatol. 2015 Feb.

Abstract

Objective: Subcutaneous (SC) abatacept (ABA) is comparable to intravenous (IV) formulation in terms of efficacy and safety profile. Our work analyzed the switch to SC formulation from IV administration in patients with rheumatoid arthritis.

Methods: Fifty-one patients treated with SC ABA were included. Clinical data were obtained from clinical charts.

Results: Fourteen patients relapsed and needed to return to the IV administration. Neither clinical and laboratory features nor the previous therapies were identified as risk factors for SC formulation inefficacy. Disease activity decreased after the return to IV infusions.

Conclusion: SC ABA showed a risk of relapse in 27% of cases. The reinsertion of the IV administration quickly reinstated disease control.

Keywords: ABATACEPT; EFFICACY; RHEUMATOID ARTHRITIS; SAFETY; SUBCUTANEOUS FORMULATION; THERAPY.

PubMed Disclaimer

Comment in

LinkOut - more resources